p-SCN-Bn-TCMC HCl
| Code | Size | Price |
|---|
| TAR-T28464-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28464-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
p-SCN-Bn-TCMC is a bifunctional chelator, it contains a powerful chelator TCMC and reactive tioisocyante linker. TCMC is a powerful chelator with capability to strongly bind radio-isotopic heavy metal ion, which are widely used for radio-diagnostic/imaging research. The thioisocynate functional group is reactive to amino and hydroxy groups, and can be used to make conjugate with peptides, antibodies and other bio-macro-molecules.
CAS:
2153478-57-8
Molecular Weight:
693.51
Purity:
0.98
SMILES:
Cl.Cl.Cl.Cl.NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)C(Cc2ccc(cc2)N=C=S)CN(CC(N)=O)CC1
References
Kasten BB, Azure MT, Schoeb TR, Fisher DR, Zinn KR. Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates. Nucl Med Biol. 2016 Jul;43(7):391-6. doi: 10.1016/j.nucmedbio.2016.04.001. Epub 2016 Apr 13. PubMed PMID: 27179247.
Westr?m S, Generalov R, B?nsdorff TB, Larsen RH. Preparation of (212)Pb-labeled monoclonal antibody using a novel (224)Ra-based generator solution. Nucl Med Biol. 2017 Aug;51:1-9. doi: 10.1016/j.nucmedbio.2017.04.005. Epub 2017 Apr 26. PubMed PMID: 28486098.
Yong K, Brechbiel M. Application of (212)Pb for Targeted ?-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci. 2015;2(3):228-245. Epub 2015 Aug 18. PubMed PMID: 26858987; PubMed Central PMCID: PMC4743765.
Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM. Safety and Outcome Measures of First-in-Human Intraperitoneal ? Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2016 Nov 30. [Epub ahead of print] PubMed PMID: 27906723; PubMed Central PMCID: PMC5449266.